年度重大进展：胰腺癌。
Top advances of the year: Pancreatic cancer.
机构信息
Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
出版信息
Cancer. 2023 Dec 15;129(24):3843-3851. doi: 10.1002/cncr.35031. Epub 2023 Sep 30.
Abstract
This commentary highlights the key recent advances made in the field of pancreatic cancer. Although there has yet to be a major breakthrough in clinical care for the majority of patients, significant strides have been made in understanding the complex biology of this malignancy and identifying new therapeutic targets.
摘要
本述评重点介绍了胰腺癌领域的最新重要进展。尽管大多数患者的临床治疗尚未取得重大突破，但在深入了解这种恶性肿瘤的复杂生物学特性以及确定新的治疗靶点方面已经取得了显著进展。
相似文献
1
Top advances of the year: Pancreatic cancer.年度重大进展：胰腺癌。
Cancer. 2023 Dec 15;129(24):3843-3851. doi: 10.1002/cncr.35031. Epub 2023 Sep 30.
2
Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy.胰腺导管腺癌中的肿瘤微环境：免疫治疗的意义。
World J Gastroenterol. 2022 Jul 21;28(27):3297-3313. doi: 10.3748/wjg.v28.i27.3297.
3
[Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects].[胰腺导管腺癌免疫微环境与免疫治疗前景]
Zhonghua Wai Ke Za Zhi. 2019 Jan 1;57(1):10-15. doi: 10.3760/cma.j.issn.0529-5815.2019.01.003.
4
Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.胰腺导管腺癌免疫治疗的合理联合方案
Chin Clin Oncol. 2017 Jun;6(3):31. doi: 10.21037/cco.2017.06.04.
5
Advances in immunotherapy for pancreatic ductal adenocarcinoma.免疫治疗在胰腺导管腺癌中的进展。
J Hepatobiliary Pancreat Sci. 2021 May;28(5):419-430. doi: 10.1002/jhbp.944. Epub 2021 Apr 3.
6
[Characteristics of pancreatic ductal adenocarcinoma immune microenvironment and related immunotherapy strategies].[胰腺导管腺癌免疫微环境特征及相关免疫治疗策略]
Zhonghua Yi Xue Za Zhi. 2021 Mar 30;101(12):831-835. doi: 10.3760/cma.j.cn112137-20201027-02938.
7
[Advances in immunotherapy of pancreatic ductal adenocarcinoma].[胰腺导管腺癌免疫治疗的进展]
Zhonghua Wai Ke Za Zhi. 2017 May 1;55(5):396-400. doi: 10.3760/cma.j.issn.0529-5815.2017.05.018.
8
Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.靶向肿瘤微环境用于胰腺癌治疗
Chin Clin Oncol. 2019 Apr;8(2):18. doi: 10.21037/cco.2019.03.02.
9
Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma.靶向胰腺导管腺癌的肿瘤微环境。
Expert Rev Anticancer Ther. 2019 Jun;19(6):473-482. doi: 10.1080/14737140.2019.1622417. Epub 2019 May 31.
10
The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy.胰腺导管腺癌的免疫格局与克服免疫治疗耐药性
Lancet Gastroenterol Hepatol. 2023 Dec;8(12):1129-1142. doi: 10.1016/S2468-1253(23)00207-8. Epub 2023 Oct 19.
引用本文的文献
1
Case report: A successful case of targeted immunotherapy for locally advanced pancreatic cancer under non-surgical conditions.病例报告：非手术条件下局部晚期胰腺癌靶向免疫治疗成功病例。
Front Immunol. 2025 Jan 10;15:1519186. doi: 10.3389/fimmu.2024.1519186. eCollection 2024.
2
Combination of mutations in genes controlling DNA repair and high mutational load plays a prognostic role in pancreatic ductal adenocarcinoma (PDAC): a retrospective real-life study in Sardinian population.控制DNA修复的基因中的突变组合和高突变负荷在胰腺导管腺癌（PDAC）中具有预后作用：一项针对撒丁岛人群的回顾性现实研究。
J Transl Med. 2024 Jan 27;22(1):108. doi: 10.1186/s12967-024-04923-3.
本文引用的文献
1
Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.新辅助FOLFIRINOX方案与直接手术治疗可切除胰头癌的比较（NORPACT-1）：一项多中心、随机、2期试验
Lancet Gastroenterol Hepatol. 2024 Mar;9(3):205-217. doi: 10.1016/S2468-1253(23)00405-3. Epub 2024 Jan 15.
2
Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy.转化生长因子-β 阻断在胰腺癌中的应用增强了联合化疗的敏感性。
Gastroenterology. 2023 Oct;165(4):874-890.e10. doi: 10.1053/j.gastro.2023.05.038. Epub 2023 May 30.
3
Uridine-derived ribose fuels glucose-restricted pancreatic cancer.尿苷衍生的核糖为葡萄糖限制的胰腺癌供能。
Nature. 2023 Jun;618(7963):151-158. doi: 10.1038/s41586-023-06073-w. Epub 2023 May 17.
4
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.个体化 RNA 新抗原疫苗可刺激胰腺癌中的 T 细胞。
Nature. 2023 Jun;618(7963):144-150. doi: 10.1038/s41586-023-06063-y. Epub 2023 May 10.
5
Hematopoietic progenitor kinase 1 inhibits the development and progression of pancreatic intraepithelial neoplasia.造血祖细胞激酶 1 抑制胰腺上皮内瘤变的发展和进展。
J Clin Invest. 2023 Jun 15;133(12):e163873. doi: 10.1172/JCI163873.
6
Adagrasib in Advanced Solid Tumors Harboring a Mutation.在携带突变的晚期实体瘤中应用阿达格拉西布
J Clin Oncol. 2023 Sep 1;41(25):4097-4106. doi: 10.1200/JCO.23.00434. Epub 2023 Apr 26.
7
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.达拉非尼联合曲美替尼治疗 BRAFV600E 突变罕见癌症：Ⅱ期 ROAR 试验。
Nat Med. 2023 May;29(5):1103-1112. doi: 10.1038/s41591-023-02321-8. Epub 2023 Apr 14.
8
Pancreatic cancer: Advances and challenges.胰腺癌：进展与挑战。
Cell. 2023 Apr 13;186(8):1729-1754. doi: 10.1016/j.cell.2023.02.014.
9
Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer.细胞自主型 CXCL1 通过中性粒细胞衍生的 TNF 在胰腺癌中维持耐受相关回路和基质炎症。
Cancer Discov. 2023 Jun 2;13(6):1428-1453. doi: 10.1158/2159-8290.CD-22-1046.
10
HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation.HMGA1 诱导 FGF19 驱动胰腺发生癌变和基质形成。
J Clin Invest. 2023 Mar 15;133(6):e151601. doi: 10.1172/JCI151601.
Zotero 插件